|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Mineral rights and properties | ||||||||||||||||||||
| Development costs | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accounts payable - related party | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Convertible note payable, net - related party | ||||||||||||||||||||
| Convertible note payable, net | ||||||||||||||||||||
| Accrued interest - related parties | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Advances payable - related party | ||||||||||||||||||||
| Advances payable | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Notes payable - related party | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred shares, 25,000,000 shares Series A preferred stock - $10.00 stated value; 2,500,000 authorized; 0 shares issued and outstanding | ||||||||||||||||||||
| Total preferred shares, 25,000,000 shares Series A preferred stock - $10.00 stated value; 2,500,000 authorized; 0 shares issued and outstanding | ||||||||||||||||||||
| Common shares, $0.001 par value; 1,000,000,000 shares authorized; 25,964,295 and 27,379,295 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Shareholders’ deficit | ||||||||||||||||||||
| Total liabilities and shareholders’ deficit | ||||||||||||||||||||
Loading...
